Journal
THERAPEUTIC DRUG MONITORING
Volume 26, Issue 2, Pages 192-199Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00007691-200404000-00019
Keywords
pharmacogenetics; polymorphism; drug clearance; drug interactions; CYP3A
Ask authors/readers for more resources
CYP3A isozymes participate in the metabolism of 4560% of currently used drugs and of a variety of other compounds such as steroid hormones, toxins, and carcinogens. The CYP3A expression status is a major determinant of drug efficacy and safety, and it may also affect an individual's predisposition to certain cancers. The interand intraindividual expression of CYP3A is variable because of a complex interplay between genetic and environmental factors. Markers predictive of the individual CYP3A activity could improve therapies with CYP3A substrates by personalised dose adjustments, but their development has been slower than for other drug-metabolizing enzymes. Here we summarize the recent progress in genomics and regulation of CYP3A. The recently described markers of the CYP3A5 and CYP3A7 polymorphisms should facilitate the development of isozyme-specific activity markers for the individual CYP3A isozymes, including CYP3A4.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available